Columbia University Herbert Irving Comprehensive Cancer Center | Strategic Alliance Partners

August 02, 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma.

July 13, 2018

Charles G. Drake, MD, PhD, discusses the importance of the CARMENA results, the future of cytoreductive nephrectomy, and how the use of immunotherapy could change treatment in this setting.

January 04, 2018

Richard Carvajal, MD, director of Experimental Therapeutics and director of the Melanoma Service at Columbia University Medical Center, discusses the biology and distinctions of extracutaneous melanoma.

January 03, 2018

Owen O'Connor, MD, PhD, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma

December 06, 2017

Owen O'Connor, MD, PhD, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

November 25, 2017

Columbia University and NewYork-Presbyterian announced today that Florence Irving and her late husband, Herbert Irving, have given $700 million to the two institutions to dramatically advance research and clinical programs for the treatment of cancer.

April 28, 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

March 08, 2017

Charles Drake, MD, PhD, discusses pairing immunotherapy with chemotherapy, the efficacy of current immunotherapy agents, and the future use of immunotherapy in the treatment of genitourinary cancers.

March 04, 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.

February 23, 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.

January 11, 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses a phase I study of ruxolitinib (Jakafi) in combination with trastuzumab (Herceptin) in metastatic HER2-positive breast cancer.

December 30, 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.

October 27, 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses the importance of developing accurate biomarkers when it comes to administering immunotherapy.

March 10, 2016

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.

January 19, 2016

Today, in his laboratory at Columbia University, Murty Vundavalli, PhD continues working to understand the genetic and epigenetic aspects of cervical cancer in an attempt to elucidate prognostic markers of response to treatment.

October 06, 2015

Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.

September 10, 2015

Owen A. O'Connor, MD, PhD, professor of Medicine and Experiment Therapies, co-program director, Lymphoid Development and Malignancy Program, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses targeting CD30 expression in patients with diffuse large B-cell lymphoma.

August 13, 2015

Owen A. O'Connor, MD, PhD, discusses the evolving use of the anti-CD30 agent brentuximab vedotin across several lymphoma types.

June 23, 2015

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

June 19, 2015

Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.